29 Jul 2019 07:00
Yourgene Health plc
("Yourgene", the "Company" or the "Group")
Appointment of Director
Manchester, UK - 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the appointment of Dr John Brown CBE to the Board of Directors as a Non-executive Director with immediate effect. Dr Brown will act as the Senior Independent Director on the Board.
Dr Brown has over 20 years' capital markets experience in the healthcare and life sciences sector. He is currently a Senior Independent Director of BioCity and Acacia Pharma and is Chairman of Cell Therapy Catapult and Synpromics. Additionally, he has previous significant board experience with roles including Chairman of Axis-Shield, Chairman of BTG, Non-executive Director of Vectura and Chief Executive Officer of Acambis.
Further disclosures on Dr Brown as required under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies are included in the appendix below.
Adam Reynolds, Chairman of Yourgene, commented: "We are delighted to welcome John to the Board of Yourgene. John has unrivalled experience in working with publicly listed life sciences businesses and we look forward to drawing on his experience as we drive awareness of Yourgene's expanded product portfolio across our target markets. John's skillset and experience is a great strategic fit as Yourgene enters the next phase of its growth journey. We look forward to leveraging the team's experience and continuing to build a truly international molecular diagnostics business."
Appendix - Appointment of Dr John Robert Brown CBE
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Dr Brown (aged 64):
Current appointments | Appointments in the last 5 years |
Acacia Pharma Group plc | BBI Diagnostics Group 2 plc |
BioCity Nottingham Limited | BioIndustry Association |
BioCity Group Limited | CXR Biosciences Limited |
Cell Therapy Catapult Limited | Electrical Geodesics Inc. |
Craigmhor Consulting Limited | Kyowa Kirin International plc |
JWEB Limited | Mode Diagnostics Limited |
Mobius Technology Limited | Quantum Pharma plc |
Synpromics Limited | Scottish LifeSciences Association |
Touch Bionics Limited | |
Vectura Group plc |
Dr Brown does not hold any share or options in the Company.
There is no further information regarding Dr Brown required to be disclosed under the AIM Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
| |
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing investors@yourgene-health.com
| Tel: +44 (0)161 667 6865
|
Cairn Financial Advisers LLP (Nomad) Liam Murray / James Caithie / Ludovico Lazzaretti
| Tel: +44 (0)20 7213 0880 |
Stifel Nicolaus Europe Limited (Sole Broker) Nicholas Moore / Matthew Blawat / Ben Maddison
| Tel: +44 (0)20 7710 7600 |
Vigo Communications (PR) Ben Simons / Fiona Henson / Antonia Pollock yourgene@vigocomms.com | Tel: +44 (0)20 7390 0238
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.